Skip to main content
Premium Trial:

Request an Annual Quote

A-Alpha Bio Secures $22.4M in Series A2 Funding

NEW YORK — A-Alpha Bio said on Tuesday that it has raised $22.4 million in a Series A2 financing round.

The round was led by Perceptive Xontogeny Ventures and included Madrona, both of which were existing investors. New investors participating in the round included Breakout Ventures.

Seattle-based A-Alpha Bio was founded in 2017 as a spinout of the University of Washington and has raised $51 million to date, including $20 million in Series A funding in late 2021, as well as non-dilutive funding from the Bill & Melinda Gates Foundation, the National Science Foundation, and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense.

The synthetic biology and machine learning company plans to use the new funding to further develop its AlphaSeq platform for measuring protein-protein interactions using genetic engineering and DNA sequencing, as well as its AlphaBind platform, which uses machine learning to train models that predict protein sequences with desired binding properties. The money will also support the development of A-Alpha Bio's pipeline of cancer therapeutics, which are currently in the discovery and validation stage.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.